Literature DB >> 33407170

Chronic active EBV infection in refractory enteritis with longitudinal ulcers with a cobblestone appearance: an autopsied case report.

Yosuke Aihara1, Kei Moriya2, Naotaka Shimozato1,3, Shinsaku Nagamatsu1, Shinya Kobayashi4, Masakazu Uejima1, Hideki Matsuo1, Eiwa Ishida5, Hideo Yagi4, Toshiya Nakatani1, Hitoshi Yoshiji3, Eiryo Kikuchi1.   

Abstract

BACKGROUND: Chronic active Epstein-Barr virus infection (CAEBV) is defined as Epstein-Barr virus (EBV)-positive T/NK cell-related neoplasia, and its major clinical symptom is systemic inflammation presenting as infectious mononucleocytosis, whereas enteritis and diarrhea are minor clinical symptoms. The complex mixture of tumorigenic processes of EBV-positive cells and physical symptoms of systemic inflammatory disease constitutes the varied phenotypes of CAEBV. Herein, we describe a case of CAEBV that was initially diagnosed as Crohn's disease (CD) based on ileal ulcers and clinical symptoms of enteritis. CASE
PRESENTATION: A 19-year-old woman complained of abdominal pain and fever. Blood examination showed normal blood cell counts without atypical lymphocyte but detected modest inflammation, hypoalbuminemia, slight liver dysfunction, and evidence of past EBV infection. The esophagogastroduodenoscopic findings were normal. However, colonoscopy revealed a few small ulcers in the terminal ileum. The jejunum and ileum also exhibited various forms of ulcers, exhibiting a cobblestone appearance, on capsule endoscopy. Based on these clinical findings, she was strongly suspected with CD. In the course of treatment by steroid and biologics for refractory enteritis, skin ulcers appeared about 50 months after her initial hospital visit. Immunohistology of her skin biopsy revealed proliferation of EBV-encoded small RNA (EBER)-positive atypical lymphocytes. We retrospectively assessed her previous ileal ulcer biopsy before treatment and found many EBER-positive lymphocytes. Blood EBV DNA was also positive. Therefore, she was diagnosed with extranodal NK/T-cell lymphoma with CAEBV-related enteritis rather than CD. She was treated with cyclosporine and prednisolone combination therapy for CAEBV-related systemic inflammation and chemotherapy for malignant lymphoma. Unfortunately, her disease continued to progress, leading to multiple organ failure and death at the age of 23 years.
CONCLUSION: Clinicians need to remember the possibility of CAEBV as a differential diagnosis of refractory enteritis. Enteritis with intestinal ulcer is a rare symptom of CAEBV, and it is impossible to acquire a definitive diagnosis by ulcer morphology only. In cases where the possibility of CAEBV remains, tissue EBVR expression should be checked by in situ hybridization and blood EBV DNA.

Entities:  

Keywords:  Biologics; Capsule endoscopy; Case report; Chronic active EBV infection; Cobblestone appearance; Crohn’s disease; Inflammatory bowel disease; Lymphoproliferative disorders; Malignant lymphoma; Refractory enteritis

Mesh:

Year:  2021        PMID: 33407170      PMCID: PMC7789587          DOI: 10.1186/s12876-020-01589-1

Source DB:  PubMed          Journal:  BMC Gastroenterol        ISSN: 1471-230X            Impact factor:   3.067


  17 in total

1.  Wireless capsule endoscopy.

Authors:  G Iddan; G Meron; A Glukhovsky; P Swain
Journal:  Nature       Date:  2000-05-25       Impact factor: 49.962

2.  Chronic active Epstein-Barr virus (CAEBV) enteritis.

Authors:  Yu-Jen Tseng; Wei-Qun Ding; Liang Zhong; Jian Chen; Zhong-Guang Luo
Journal:  Int J Infect Dis       Date:  2019-02-23       Impact factor: 3.623

3.  Chronic Active Epstein-Barr Virus Associated Enteritis May Develop into a Precancerous Disease.

Authors:  Yu Zhang; Zhinong Jiang; Rongbei Liu; Haotian Chen; Mengyu Wang; Qian Cao
Journal:  Inflamm Bowel Dis       Date:  2017-05       Impact factor: 5.325

Review 4.  How to Diagnose and Treat IBD Mimics in the Refractory IBD Patient Who Does Not Have IBD.

Authors:  Karen A Chachu; Mark T Osterman
Journal:  Inflamm Bowel Dis       Date:  2016-05       Impact factor: 5.325

5.  EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases.

Authors:  Hiroshi Kimura; Yoshinori Ito; Shinji Kawabe; Kensei Gotoh; Yoshiyuki Takahashi; Seiji Kojima; Tomoki Naoe; Shinichi Esaki; Atsushi Kikuta; Akihisa Sawada; Keisei Kawa; Koichi Ohshima; Shigeo Nakamura
Journal:  Blood       Date:  2011-11-16       Impact factor: 22.113

6.  Severe chronic active Epstein-Barr virus infection mimicking steroid-dependent inflammatory bowel disease.

Authors:  Daniel E Roth; Adrian Jones; Lesley Smith; Raymond Lai; Jutta Preiksaitis; Joan Robinson
Journal:  Pediatr Infect Dis J       Date:  2005-03       Impact factor: 2.129

7.  Adenovirus type-2 in a patient with lethal hemorrhagic colonic ulcers and chronic active Epstein-Barr virus infection.

Authors:  M Okano; G M Thiele; J R Davis; W M Nauseef; F Mitros; D T Purtilo
Journal:  Ann Intern Med       Date:  1988-05       Impact factor: 25.391

8.  The clinicopathologic features of chronic active Epstein-Barr virus infective enteritis.

Authors:  Rongbei Liu; Mengyu Wang; Lizhi Zhang; Weixun Zhou; Ying Huang; Hong Guo; Yubei Gu; Yan Chen; Yuqin Li; Chunxiao Chen; Yufang Wang; Lan Rong; Ji Li; Jiaqi Xu; Qian Cao; Zhinong Jiang
Journal:  Mod Pathol       Date:  2018-10-08       Impact factor: 7.842

Review 9.  Advances in the Study of Chronic Active Epstein-Barr Virus Infection: Clinical Features Under the 2016 WHO Classification and Mechanisms of Development.

Authors:  Ayako Arai
Journal:  Front Pediatr       Date:  2019-02-05       Impact factor: 3.418

10.  Capsule endoscopy findings for the diagnosis of Crohn's disease: a nationwide case-control study.

Authors:  Motohiro Esaki; Takayuki Matsumoto; Naoki Ohmiya; Ema Washio; Toshifumi Morishita; Kei Sakamoto; Hiroo Abe; Shojiro Yamamoto; Tetsu Kinjo; Kazutomo Togashi; Kenji Watanabe; Fumihito Hirai; Masanao Nakamura; Sadaharu Nouda; Shinya Ashizuka; Teppei Omori; Shuji Kochi; Shunichi Yanai; Yuta Fuyuno; Atsushi Hirano; Junji Umeno; Takanari Kitazono; Fukunori Kinjo; Mamoru Watanabe; Toshiyuki Matsui; Yasuo Suzuki
Journal:  J Gastroenterol       Date:  2018-09-15       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.